T1D Exchange

"I have diabetes. Diabetes doesn't have me."

For Keiva Cheney, those words became a daily reminder that a diagnosis does not define what's possible.

Through The Diamend Foundation, Keiva is creating spaces where people with diabetes can find connection, confidence, and community—particularly for those whose voices and experiences have too often been overlooked.

Read her inspiring story and see how she's transforming lived experience into meaningful impact.

https://t1dx.co/4uQcziJ

See if you’re eligible for the VX-880-101 clinical trial!

Researchers at Vertex Pharmaceuticals are studying an investigational cell therapy for people with T1D. Eligible participants may receive compensation for study-related time.

Find a study site and learn more: https://t1dx.co/4esmypF

Are you living with T1D and experiencing nighttime lows?

You may qualify for a Phase 2 clinical trial evaluating a medication designed to help prevent overnight hypoglycemia.

Zucara Therapeutics has recently added 10 new study locations across the U.S., so even if you weren’t eligible before, you might qualify now!

- Ages 18-75
- Living with T1D for at least 5 years

Take a short questionnaire to find out if you're eligible: https://t1dx.co/4eHWN3B

Juggling airports, shifting time zones, and managing unpredictable blood glucose levels— traveling with T1D is a balancing act. ✈️

Preparation is everything: Pack smart, plan ahead, and expect the unexpected.
In this article, learn how to stay ready wherever you’re headed!

https://t1dx.co/4vkQJVU

Are you between the ages of 18 and 50, living in the Chicago area?

If you have T1D and frequently experience irregular sleep, consider participating in a study to better understand the relationship between sleep and T1D management!

Learn more: https://t1dx.co/43A6SdP

New look, same T1D Exchange!

Your experiences matter. By sharing your perspective, answering Question of the Day, participating in research, or engaging with our community, you're helping advance a better future for everyone impacted by type 1 diabetes.

Because real change starts with real people.

Stay connected: https://t1dx.co/4esOyZ6

Thank you to everyone who attended our sessions, visited our booth, and connected with the T1D Exchange team during the American Diabetes Association (ADA)’s 86th Scientific Sessions!

From oral presentations and poster sessions to symposium discussions, the T1D Exchange team and partners shared new findings throughout the conference.

Check out our full ADA 2026 research recap, including presentation highlights and key takeaways: https://t1dx.co/3Slw5WR

Many people with T1D struggle with frequent overnight lows.

That’s why a clinical trial is now enrolling adults with T1D to study a medication that may help reduce nighttime hypoglycemia.

Zucara Therapeutics’ trial has expanded to 10 new locations nationwide. If you checked before and weren’t eligible, now is a great time to look again!

You could potentially qualify if you:
☑️ Are between 18 and 75 years old
☑️ Were diagnosed with T1D 5+ years ago

Learn more and take a quick questionnaire to see if you’re a match: https://t1dx.co/4e18Icq

After 13 years of living with type 1 diabetes, Katie Beth Hand did something she never thought possible: She stopped taking insulin.

Katie Beth is participant No. 9 in an experimental islet cell transplant study at UChicago Medicine. She received donor-derived islet cells, which are protected by ongoing infusions of Tegoprubart — a new, targeted immune therapy. Within seven weeks of her transplant, she achieved insulin independence.

In our latest article, Katie Beth shares why she enrolled in this groundbreaking clinical trial, what the transplant process was really like, and how life has changed since.

Read the full story now!

https://t1dx.co/4xbEb4s

Do you have T1D and a history of severe lows?

Vertex Pharmaceuticals’ VX-880-101 clinical trial is currently recruiting people with T1D ages 18-65. This study is evaluating an investigational islet cell therapy in T1D.

See if you may be eligible: https://t1dx.co/4wS3W9G